Elastomeric infusion pumps provide an advantageous solution for continuous subcutaneous drug delivery for conditions requiring long-term outpatient treatment. These portable, lightweight pumps function via the elastic properties of special medical-grade polymers that stretch under positive pressure and slowly return to their original shape, facilitating a metered and consistent infusion of medications such as analgesics, antibiotics, chemotherapy drugs, and other therapies.
Global elastomeric infusion pumps market is estimated to be valued at USD 1,255.4 Mn in 2025 and is expected to exhibit a CAGR of 9.4% during the forecast period (2025-2032).
B. Braun Melsungen AG, Fresenius Kabi, Leventon, S.A.U, Ambu A/S, Baxter International Inc., Halyard Health, and Nipro Corporation.
Key opportunities: Increasing incidence of chronic diseases necessitating long-term outpatient therapy and the growing geriatric population susceptible to such conditions provide lucrative opportunities for players in this market.
Market drivers
Growing prevalence of cancer and other chronic diseases: The increasing burden of cancer and rise in chemotherapy treatment prescriptions is a major factor fueling demand for elastomeric pumps that facilitate ambulatory chemotherapy infusions in a comfortable, low-cost manner.
Elastomeric Infusion Pumps Market Demand is facing several challenges currently. Factors such as product recalls due to safety concerns, risks of inaccurate dosages, and device malfunctions are negatively impacting market growth. The pumps also have limitations in delivering critical medications intravenously at specialized flow rates. In addition, the pumps require proper programming and are not suitable for patients requiring precise and programmable delivery methods. Managing batteries and keeping devices charged is another issue limiting adoption. Overall, reliability and safety concerns surrounding elastomeric pumps are posing significant challenges for players in this industry.
SWOT Analysis
Strengths: Elastomeric pumps are portable, inexpensive devices for continuous subcutaneous drug delivery. They provide benefits of ambulatory infusion without tubing or needles.
Weaknesses: Pumps have limited medication capacity and delivery accuracy. Changes in ambient pressure/temperature can affect infusion accuracy.
Opportunities: Growing incidence of chronic diseases necessitating long-term drug therapies presents opportunities. Technological advancements improving reliability and precision also provide scope.
Threats: Strict regulations and safety standards impose compliance challenges. Newer infusion technologies pose threat of substitution.
North America currently accounts for the largest share of the elastomeric infusion pumps market, in terms of value. This is attributed to the growing prevalence of chronic diseases in the region necessitating long-term drug infusion therapies. According to estimates, the North America market is projected to reach a value of USD XX Million by 2031.
Asia Pacific is touted to be the fastest growing regional market for elastomeric infusion pumps. Factors such as rising healthcare expenditures, increasing focus on quality healthcare infrastructure, and growing geriatric population susceptible to chronic diseases are fueling market growth in the Asia Pacific region. The market in the region is projected to expand at a CAGR of over 9.2% during the forecast period.
Get this Report in Japanese Language:
Get this Report in Korean Language:
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment